Hyoscyamine

Generic Name
Hyoscyamine
Brand Names
Anaspaz, Donnatal, Ed Spaz, Hyophen, Levbid, Levsin, Nulev, Oscimin, Phenohytro, Phosphasal, Symax, Urelle, Uribel, Urimar Reformulated Oct 2013, Urin DS, Urogesic Blue Reformulated Apr 2012, Ustell, Utira
Drug Type
Small Molecule
Chemical Formula
C17H23NO3
CAS Number
101-31-5
Unique Ingredient Identifier
PX44XO846X
Background

Hyoscyamine is a tropane alkaloid and the levo-isomer of atropine. It is commonly extracted from plants in the Solanaceae or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.

Although hyoscyamine is marketed in the United States, it is not FDA approved.

Indication

As a drug that is not FDA approved, hyscyamine has no official indications. Intravenous hysocyamine has been used to reduce gastric motility, reduce pancreatic pain and secretions, to facilitate imaging of the gastrointestinal tract, treat anticholinesterase toxicity, treat certain cases of partial heart block, improve visualization of the kidneys, and for symptomatic relief of biliary and renal colic. Intravenous hyoscyamine is also used pre-operatively to reduce secretions of the mouth and respiratory tract to facilitate intubation. Oral hyoscyamine is used to treat functional intestinal disorders, for symptomatic relief of biliary and renal colic, and symptomatic relief of acute rhinitis.

Associated Conditions
Biliary Colic, Colic, Cystitis, Diverticulitis, Heart Block, Irritable Bowel Syndrome (IBS), Neurogenic Bladder, Neurogenic Bowel Dysfunction, Pancreatitis, Parkinsonism, Peptic Ulcer, Poisoning caused by anticholinesterases, Pylorospasm, Renal Colic, Spastic bladder, Tracheo-bronchial secretion excess, Acute Enterocolitis, Acute Rhinitis, Gastric secretions, Mild Dysentery, Pharyngeal secretions, Salivary secretions, Spastic colitis
Associated Therapies
-

Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation

First Posted Date
2018-11-23
Last Posted Date
2024-12-03
Lead Sponsor
University of Kansas Medical Center
Target Recruit Count
5
Registration Number
NCT03750656
Locations
🇺🇸

University of Kansas Medical Center, Kansas City, Kansas, United States

Efficacy of Open Label Placebo in Children With FGIDs

First Posted Date
2015-03-17
Last Posted Date
2021-07-23
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
31
Registration Number
NCT02389998
Locations
🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath